BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
4 reports, 2 independent
Updated Sep 9
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.BridgeBio officially submitted the NDA for infigratinib to the FDA.1 source
BridgeBio plans to submit MAA and NDA for infigratinib review to the FDA.1 source
Keep exploring
The entities involved
Related events
- OS Therapies, Inc. is seeking interim and final review data submissions from regulatory bodies while attending major global investment conferences.
- Immuron anticipates receiving FDA approval for its IND submission.
- Data was presented in Athens supporting a future U.S. NDA submission to the FDA.
- Annovis Bio discussed p-tau217 use with the FDA and plans to submit an NDA for review.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.